High-throughput Screening

High-throughput Screening

Drug failure in the clinic is most often attributed to either unforeseen toxicity or a lack of demonstrated efficacy. Thus, predictive in vitro models that more accurately reflect in vivo disease states can inform the preclinical processes of drug discovery and development ensuring higher success rate in the eventual clinical setting. CDI’s iCell and MyCell products offer a wide range of innate, engineered, and induced disease models for screening, hit-to-lead, and lead optimization efforts. The cells are amenable to gene modulation and culture in high-density multiwell plates. iCell and MyCell products have been used in high-throughput screens across various disease areas including infectious disease, neurological disorders, diabetes, and cardiomyopathies.